INTRODUCTION
============

Falls occur in one-third of all adults over 65 years old, often leading to decreased independence and mobility and increased morbidity^([@b1-ijtmb-5-3-28])^, as well as to increased associated health care costs that are expected to reach \$32 billion by 2020^([@b2-ijtmb-5-3-28])^. While extensive research has been completed to understand the cause and possible interventions for this issue^([@b3-ijtmb-5-3-28]--[@b12-ijtmb-5-3-28])^, options need to be developed which will provide older adults with treatments that can help them stay active, healthy, and independent long into their senior years. A nonpharmaceutical intervention is especially important, considering the cost, interactions, and side-effects of the multiple medications seniors often require.

Influence of the visual system is thought to be a primary factor in falls in older individuals^([@b13-ijtmb-5-3-28]--[@b16-ijtmb-5-3-28])^. However, balance impairments^([@b17-ijtmb-5-3-28])^, cardiovascular^([@b18-ijtmb-5-3-28])^, and neurological factors^([@b19-ijtmb-5-3-28]--[@b20-ijtmb-5-3-28])^ are reportedly involved in falls in this population. Postural instability may be increased by compensation for muscle imbalances, pain, current or prior musculoskeletal injury, excessive cocontractions, or inappropriate muscle activity^([@b16-ijtmb-5-3-28],[@b21-ijtmb-5-3-28]--[@b24-ijtmb-5-3-28])^. With these factors in mind, a few studies have assessed balance training, exercise, yoga, and other interventions with inconclusive results^([@b25-ijtmb-5-3-28]--[@b26-ijtmb-5-3-28])^.

If therapeutic massage (TM) can restore muscle balance and function, restore appropriate activation, decrease spasms, correct postural imbalances, or improve gait or movement confidence, it may have a beneficial effect on postural stability. TM has been shown to influence blood flow, motoneuron pool excitability, muscle activation, and joint range of motion^([@b27-ijtmb-5-3-28]--[@b32-ijtmb-5-3-28])^, suggesting that TM may have an indirect effect on postural control. Moreover, as clinicians we are trained to be aware of possible instability immediately after a TM session, which may be due to decreased blood pressure, blood glucose levels, changes in relaxation state, and other factors. We have seen this effect in our clients; however, no research to date has investigated the possible decrease in postural stability immediately following treatment, or if stability improves with time after the treatment is complete. The clinical evidence combined with the research to date suggests that TM should be investigated as a possible intervention to improve postural stability. Clearly, the population most benefiting from improved postural stability would be our older adults.

Most studies have assessed the effects of a single treatment session. However, understanding the long-term effects of regular treatments is critical to the development of safe and effective intervention protocols.

In a related study, we described the short-term effects of TM for the week one session. In the present paper, we examine whether the short-term benefits of MT found at week one were replicated in the final week six session. In addition, we examine whether TM had long-term benefits by comparing the TM and control groups at week six and a follow-up assessment at week seven (both adjusted for week one baseline measures). We hypothesized that six weeks of TM treatments would produce: 1) an immediate increase in instability; 2) increasing stability and decreased cardiovascular measures over time; and 3) improved long-term stability and cardiovascular functioning by week six continuing at week seven. If TM is found to improve balance, it could be utilized as a safe and nonpharmacological preventative intervention to decrease falls in older populations.

METHODS
=======

Experimental Design
-------------------

For the six week data, a 2 × 4 \[treatment condition X time (weeks)\] mixed factorial experimental design for cardiovascular and balance variables was utilized. Independent variables were treatment with two levels (control, TM) and time with four levels (pretreatment baseline, immediate post-treatment, 20-minute post-treatment, and 60-minute post-treatment). Dependent variables included balance, heart rate, and systolic and diastolic blood pressure. Motoneuron pool excitability measures were assessed only at pretreatment and at 60-minute follow-up (2 × 2 mixed design). The testing occurred during the 1st, 6th, and 7th weeks only. Week seven was follow-up only, with no treatment and only one testing time point ([Figure 1](#f1-ijtmb-5-3-28){ref-type="fig"}). Sample size calculations were conducted a priori, based on power considerations for the linear mixed model growth curve analyses. Minimum sample size for detecting treatment effects were determined using the Hedeker, Gibbons, and Waternaux method^([@b33-ijtmb-5-3-28])^. This approach estimates sample sizes for multilevel modeling of longitudinal data with a two-group treatment effect.

![Diagram of study design and data collection time points.](ijtmb-5-3-28f1){#f1-ijtmb-5-3-28}

Participants
------------

Thirty-five volunteers participated (19 male and 16 female; ages 62.9 ± 4.6). As with study one^([@b34-ijtmb-5-3-28])^, participants were recruited through the use of brochures and posters in area physicians' offices, fitness facilities, libraries, stores, and by word of mouth. Inclusion criteria included individuals aged 50--69, with no history of a chronic disease that affects balance, cardiovascular health, or nervous system function, or arteriosclerosis, atherosclerosis, rheumatoid arthritis, diabetes, prior cancers, systemic disease, kidney disease, vestibular conditions, stroke, or any acute disease or illness causing a significant fever (\> 101.5°F), any contagious disease, an unstable health condition, or currently taking medications such as blood thinners, or any drug that affects the muscles or nerves, or influences balance. Information on regular physical activity was collected, but was not an inclusion or exclusion factor. Exclusion criteria included medications/illness affecting the measures or preventing participation in TM. Participants were randomly assigned to the control/treatment groups after signing written informed consent. All procedures were approved by the Institutional Review Board.

Intervention
------------

The treatment group received a 60-minute full-body TM ([Table 1](#t1-ijtmb-5-3-28){ref-type="table"}) using massage gel (Biotone Therapy Products, San Diego, CA, USA). Three nationally certified, state licensed Massage Therapists with 3--15 years of general experience were trained in the TM protocol by the study PI to standardize treatments, with normal individual variations between treatments and sessions, providing a more clinically applicable result. The relaxation control group rested quietly in the TM room instead of receiving treatment. Participants were requested not to reveal their treatment group to the testing investigator, who was blinded to the treatment condition. Testing occurred at the same time each day, immediately prior to, and after, the TM.

###### 

Standardized 60-minute TM Protocol^([@b34-ijtmb-5-3-28])^

  -------------------------------------------------------------------------------------------------------------------------------------- ------------
  ***Bilaterally (supine):***                                                                                                            
  Gliding (effleurage), general neck/shoulders, spread cream                                                                             2 minutes
  Head and face -- without massage cream                                                                                                 2 minutes
  Gentle stroking, pressure points, kneading and scalp scrub                                                                             
  Kneading (petrissage); neck/shoulders                                                                                                  2 minutes
  Friction-gliding                                                                                                                       
  Kneading (petrissage); upper trapezius, levator scapula                                                                                
  The following strokes will be done on one side, then the other:                                                                        5 minutes
  Friction -- circular; beginning at the occiput, moving lateral to mastoid process                                                      
  Friction -- gliding                                                                                                                    
  Direct pressure (trigger point); from occiput, moving lateral to mastoid process                                                       
  Friction -- circular; from occiput, moving lateral to mastoid process                                                                  
  The following strokes will be done bilaterally:                                                                                        5 minutes
  Kneading (petrissage); upper trapezius, levator scapula, scalenes                                                                      
  Friction -- circular; scalenes                                                                                                         
  Friction -- gliding, stripping; scalenes (using lighter pressure on older individuals is recommended as per general MT guidelines)     
  Direct pressure (trigger point); trapezius, levator scapula, scalene (see pressure comment above)                                      
  Gliding (effleurage); general neck/shoulders                                                                                           1 minute
  ***Arm (left, supine):***                                                                                                              
  Gliding (effleurage), over anterior/posterior arm, spread cream                                                                        5 minutes
  Shaking at the glenohumeral joint (supporting the wrist, gently lift the arm and shake providing movement at the glenohumeral joint)   
  Kneading (petrissage); over lower, upper arm and hand                                                                                  
  ***Leg (left, then right; supine):***                                                                                                  
  Gliding (effleurage), over anterior leg, spread cream                                                                                  5 minutes
  Kneading (petrissage); over lower, upper leg                                                                                           
  Gliding, kneading of dorsum of foot, gentle traction of toes and movement of phalanges                                                 
  ***Arm (right, supine):***                                                                                                             
  Repeat as described under left arm above                                                                                               5 minutes
  Have participant roll over and position prone with bolster under ankles, insure comfort                                                
  ***Leg (right, then left; prone)***                                                                                                    
  Gentle compressions of gluteal muscles, and shaking of leg                                                                             5 minutes
  Gliding (effleurage), over posterior leg, spread cream                                                                                 
  Kneading (petrissage); over lower, upper leg                                                                                           
  Gliding, kneading of bottom of foot, gentle friction, flex knee, lift whole leg and gently shake providing motion the hip              
  Repeat on left leg                                                                                                                     5 minutes
  ***Back (prone):***                                                                                                                    
  Gliding (effleurage), over back, spread cream                                                                                          15 minutes
  Kneading (petrissage) over back                                                                                                        
  Transverse or circular friction over erector spinae                                                                                    
  Kneading, and trigger point work as needed around scapula, and along trapezius                                                         
  Finish -- gliding (effeurage), shaking, closure, breathing                                                                             3 minutes
  -------------------------------------------------------------------------------------------------------------------------------------- ------------

Within these guidelines, the Therapist adapted the specific therapeutic decisions to their experience and the comfort/needs of the client.

Assessments
-----------

Assessments were conducted as described in part one of this study^([@b34-ijtmb-5-3-28])^.

### Static and functional balance

Center of pressure (COP) measures were completed using a computerized balance platform (AccuSway Force Plate, Advanced Medical Technology, Inc., Watertown, MA, USA) and balance Clinic software (Advanced Mechanical Technology, Inc. Watertown, MA, USA). Sampling occurred at 100 Hz using a low-pass, fourth-order Butterworth filter with the cutoff frequency set at 5 Hz. Participants completed four stance conditions on the force platform---two for static balance (eyes-open, double-leg stance and eyes-closed, double-leg stance) and two for functional balance (eyes-open single-leg stance and eyes-closed single-leg stance, [Figure 2(a) and (b)](#f2-ijtmb-5-3-28){ref-type="fig"}. Each stance condition was sampled three times, for 20 seconds, with 30-seconds rest between sessions. Averages of the rectangular displacement area and average displacement velocity (V~Avg~) were used as the primary outcome measures.

![Double- and single-legged stance. (a) A double-leg stance for the static balance test and H-reflex testing was assumed with two feet placed shoulder width apart and with hands on the hips. (b) A single-leg stance for the functional balance test and H-reflex testing was assumed with the non-stance extremity standardized in a position of 30 degrees of hip flexion and 90 degrees of knee flexion, with the ankle relaxed.](ijtmb-5-3-28f2){#f2-ijtmb-5-3-28}

### Motoneuron pool excitability (Hoffmann Reflex, H-reflex)

Electrodes were applied on the dominant extremity, as previously described^([@b35-ijtmb-5-3-28])^. Briefly, the skin was prepared and recording electrodes were placed on the soleus muscle, the stimulating electrode over the posterior tibial nerve in the popliteal fossa, the dispersal pad on the ipsilateral suprapatellar region, and the ground electrode over the ipsilateral lateral malleolus. The double-leg soleus maximum H-reflex (H~max~) and maximum M-wave (M~max~) were determined. Electromyographic output (MP 150, Biopac Systems Inc. Goleta, CA) was differentially amplified 500--2000 times, and filtered at 10--1000 Hz bandwidth. The peak-to-peak amplitude of H~max~ and M~max~ was recorded during the pre- and postintervention periods. An average of seven stimulation trials were calculated for H~max~/M~max~ ratio which was used as a measure of soleus α-motoneuron pool excitability.

### Paired-reflex depression protocol (PRD)

A PRD protocol was used to assess the influence of activation history on motoneuron pool excitability in a double- and single-leg stance. This allows the assessment of changes that occurs before the synapse. PRD was measured^([@b36-ijtmb-5-3-28])^ as the percent depression of the conditioned H-reflex peak (two equal-magnitude pulses separated by 80 msec) relative to the nonconditioned H-reflex peak. The test stimulus standardized at 35% of the soleus M~max~^([@b37-ijtmb-5-3-28])^. Average of the seven trials was calculated and used for analysis.

### Recurrent inhibition (RI) protocol

An RI protocol was used as previously described^([@b38-ijtmb-5-3-28])^ to assess postsynaptic modulation of soleus motoneuron pool excitability. PRD looks at changes before the synapse, while RI assesses changes after the synapse that are primarily due to the effect of Renshaw cell activity. RI was calculated as the percent difference between the amplitude of the H-reflex with and without the conditioning stimulus. The conditioning stimulus was 25% of the soleus M~max~, followed 10 msec later by a second stimulus set at M~max~. Average of the seven trials was calculated and used for analysis.

### Heart rate and blood pressure

An automatic digital blood pressure monitor (Model: UA-787, A&D Engineering Inc, San Jose, California) was used to measure heart rate and blood pressure. Systolic/diastolic blood pressures and heart rate were recorded after resting quietly; two recordings were taken with 5 minutes between measurements. Heart rate and blood pressure were initially recorded subsequent to static and functional balance tests. Midway in the study, it was determined the participants' frustration with the eyes-closed single-leg stance condition may be confounding the results and measurements were moved to the beginning of each testing session. A statistical analysis was conducted to determine if an effect of testing order was present. Average of the two trials for systolic/diastolic blood pressures and heart rate were calculated and used for analysis.

Statistical Analysis
--------------------

Analysis of covariance (ANCOVA) was used to compare the treatment and control groups on immediate post-treatment postural control and cardiovascular measures, with pretreatment baseline measures used as covariates. In these analyses, higher baseline-adjusted post-treatment means on postural control outcomes in the TM group would suggest that TM produced initial instability in the treatment group relative to controls. Assessment for postintervention balance and cardiovascular changes across time (immediate post-treatment, 20-, and 60-minutes post-treatment) were evaluated using linear growth curve modeling for predicting post-treatment outcomes from treatment condition, time, and the interaction of treatment with time, with pretreatment baseline measures used as covariates \[two-tailed tests; *p* \< .05 significance level; linear mixed models module of SPSS (version 19, IBM SPSS Statistics, Chicago, IL, USA)\]. In the growth curve analyses, a significant interaction of treatment with time provides evidence for different treatment post-treatment outcome trajectories for the MT and control groups. Because motoneuron pool variables were assessed only pretreatment and 60 minutes post-treatment, ANCOVA (rather than growth curve analysis) was used to compare groups on motoneuron pool excitability measures at the 60-minute follow-up assessment, adjusting for pretreatment baseline. Finally, Pearson's correlations comparisons were used to assess potential relationships between the H-reflex and postural control variables. Past studies have suggested that H-reflex changes are related to changes in postural control^([@b11-ijtmb-5-3-28],[@b13-ijtmb-5-3-28])^. While correlations do not suggest cause and effect, a significant relationship does indicate that postural control and H-reflex measures do bear some connection that may be worth further investigation.

Long-Term Effects of Treatment
------------------------------

The analyses described above examined the effects of a single session of TM (at week 6, the final session of the 6-week intervention protocol) on postsession outcomes. We also examined whether the intervention had long-term effects on resting-level (baseline) outcomes assessed at week 6 (baseline prior to TM session) and week 7 (an assessment-only follow-up with no TM session provided). To test the long-term effects of MT, analysis of covariance (ANCOVA) was used to compare the MT and control groups on week 6 pretreatment baseline outcome and on week 7 (assessment only) outcomes, using week 1 baseline measures as covariates. In these analyses, significant differences between the TM and control groups on adjusted means at week 6 or week 7 (adjusted for week 1 baselines) would indicate differential long-term treatment effects on outcomes.

RESULTS
=======

Descriptive statistics for all outcomes are presented in Table 2([a](#t2a-ijtmb-5-3-28){ref-type="table"}--[c](#t2c-ijtmb-5-3-28){ref-type="table"}). [Tables 3](#t3-ijtmb-5-3-28){ref-type="table"}--[6](#t6-ijtmb-5-3-28){ref-type="table"} present the results for statistical tests of short-term, postsession effects of TM in week six. [Table 7](#t7-ijtmb-5-3-28){ref-type="table"} presents week six correlations between H-reflex variables and postural control. [Table 8](#t8-ijtmb-5-3-28){ref-type="table"} presents the ANCOVA analyses testing the long-term effects of TM on presession baseline measures at week six and on week seven measures.

###### 

Descriptive Statistics for Pre- and Postcondition Cardiovascular Measures in the Treatment and Control Groups \[Mean (Standard Deviation)\]

  *Variable*   *6^th^ week pre (TM)*   *6^th^ week pre (C)*   *6^th^ week 0 min. post (TM)*   *6^th^ week 0 min. post (C)*   *6^th^ week 20 min. post (TM)*   *6^th^ week 20 min. post (C)*   *6^th^ week 60 min. post (TM)*   *6^th^ week 60 min. post (C)*   *7^th^ week (TM)*   *7^th^ week (C)*
  ------------ ----------------------- ---------------------- ------------------------------- ------------------------------ -------------------------------- ------------------------------- -------------------------------- ------------------------------- ------------------- ------------------
  HR           76.2 (12.3)             67.5 (12.6)            68.9 (10.2)                     63.4 (11.4)                    69.1 (9.2)                       61.7 (10.7)                     69.6 (8.7)                       62.3 (13.0)                     71.2 (10.7)         68.6 (16.1)
  SBP          127.1 (21.8)            130.3 (12.9)           129.8 (13.7)                    130.5 (15.8)                   127.0 (15.0)                     132.3 (24.7)                    131.0 (17.4)                     125.8 (17.7)                    121.7 (13.8)        136.0 (22.9)
  DBP          75.4 (14.0)             79.0 (7.3)             79.8 (13.6)                     76.5 (11.1)                    77.6 (11.5)                      77.5 (11.9)                     76.9 (11.9)                      77.3 (9.9)                      76.3 (10.4)         78.7 (12.7)

TM = therapeutic massage group; C = control group; HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure.

###### 

Descriptive Statistics for Pre- and Postcondition Postural Control Measures in the Treatment and Control Groups \[Mean (Standard Deviation)\]

  *Variable*        *6^th^ week pre (TM)*   *6^th^ week pre (C)*   *6^th^ week 0 min. post (TM)*   *6^th^ week 0 min. post (C)*   *6^th^ week 20 min. post (TM)*   *6^th^ week 20 min. post (C)*   *6^th^ week 60 min. post (TM)*   *6^th^ week 60 min. post (C)*   *7^th^ week (TM)*   *7^th^ week (C)*
  ----------------- ----------------------- ---------------------- ------------------------------- ------------------------------ -------------------------------- ------------------------------- -------------------------------- ------------------------------- ------------------- ------------------
  Area Rect. EODL   0.47 (0.52)             0.83 (1.24)            1.20 (2.67)                     0.67 (0.62)                    0.80 (1.41)                      0.68 (1.07)                     0.46 (0.36)                      0.58 (0.75)                     0.26 (0.13)         1.74 (2.34)
  Area Rect. ECDL   0.79 (0.65)             1.25 (1.20)            1.14 (0.87)                     0.79 (0.48)                    0.80 (0.77)                      0.82 (0.35)                     0.71 (0.38)                      0.92 (0.69)                     0.55 (0.22)         1.35 (1.06)
  Area Rect. EOSL   1.51 (1.26)             1.23 (1.00)            1.62 (1.57)                     1.08 (0.68)                    1.08 (0.44)                      1.51 (1.86)                     1.01 (0.39)                      1.73 (2.67)                     1.36 (1.20)         1.58 (0.99)
  Area Rect. ECSL   5.04 (2.71)             3.90 (1.07)            4.84 (2.74)                     4.80 (3.95)                    5.09 (1.78)                      5.11 (5.01)                     5.16 (2.08)                      5.19 (2.45)                     4.63 (2.00)         3.02 (0.98)
  V~Avg~ EODL       0.59 (0.30)             0.86 (0.74)            0.69 (0.69)                     0.51 (0.06)                    0.70 (0.68)                      0.48 (0.07)                     0.50 (0.09)                      0.70 (0.69)                     0.48 (0.07)         1.36 (1.11)
  V~Avg~ ECDL       0.83 (0.40)             1.06 (0.66)            0.88 (0.56)                     0.70 (0.14)                    0.72 (0.28)                      0.83 (0.41)                     0.67 (0.17)                      0.79 (0.45)                     0.73 (0.23)         1.11 (0.55)
  V~Avg~ EOSL       1.89 (0.83)             1.59 (0.48)            1.60 (0.79)                     1.33 (0.55)                    1.35 (0.36)                      1.40 (0.42)                     1.26 (0.36)                      1.54 (0.88)                     1.77 (0.78)         1.89 (0.58)
  V~Avg~ ECSL       2.37 (1.40)             2.81 (2.53)            2.39 (1.20)                     2.23 (1.32)                    2.41 (1.18)                      2.58 (1.66)                     2.28 (1.13)                      2.74 (1.06)                     2.44 (1.39)         1.85 (0.85)

TM = therapeutic massage group; C = control group; Area Rect = area rectangular; V~avg~ = average velocity; EODL = eyes-open double-leg; ECDL = eyes-closed double-leg; EOSL = eyes-open single-leg; ECSL = eyes-closed single-leg.

###### 

Descriptive Statistics for Pre- and Postcondition Reflex Measures in the Treatment and Control Groups \[Mean (Standard Deviation)\]

  *Variable*      *6^th^ week pre (TM)*   *6^th^ week pre (C)*   *6^th^ week 0 min. post (TM)*   *6^th^ 0 min. week post (C)*   *6^th^ week 20 min. post (TM)*   *6^th^ week 20 min. post (C)*   *6^th^ week 60 min. post (TM)*   *6^th^ week 60 min. post (C)*   *7^th^ week (TM)*   *7^th^ week (C)*
  --------------- ----------------------- ---------------------- ------------------------------- ------------------------------ -------------------------------- ------------------------------- -------------------------------- ------------------------------- ------------------- ------------------
  H~max~/M~max~   0.27 (0.16)             0.26 (0.16)                                                                                                                                            0.19 (0.11)                      0.29 (0.22)                     0.24 (0.12)         0.20 (0.13)
  PRD 2L          62.29 (18.50)           56.45 (24.40)                                                                                                                                          65.3 (20.40)                     67.52 (17.30)                   68.13 (18.60)       68.49 (12.33)
  RI 2L           55.21 (29.60)           58.40 (26.40)                                                                                                                                          56.50 (20.30)                    53.12 (24.50)                   78.21 (10.08)       79.44 (10.77)
  PRD 1L          62.54 (24.00)           58.68 (17.30)                                                                                                                                          67.36 (18.90)                    61.83 (17.50)                   71.32 (17.22)       64.62 (15.33)
  RI 1L           80.09 (15.50)           70.58 (17.10)                                                                                                                                          76.11 (11.1)0                    69.09 (16.40                    80.17 (10.29)       72.86 (16.67)

TM = therapeutic massage group; C = control group; H~max~ = maximum H-reflex; M~max~ = maximum M-wave; PRD 2L = pair reflex depression 2 leg; PRD 1L = pair reflex depression 1 leg; RI 2L = recurrent inhibition 2 leg; RI 1L = recurrent inhibition 1 leg.

###### 

Analyses of Covariance Predicting Immediate Post-TM Outcomes (Adjusted for Baseline) at Week 6

                          *Treatment*   *Control*                  
  ----------------------- ------------- ----------- ------- ------ ----------------------------------------------------
  Displacement Area                                                
    Rect.: EODL           1.38          .45         .37     .68    1.51
    Rect.: ECDL           1.15          .15         .66     .22    3.16
    Rect.: EOSL           1.41          .19         1.21    .29    0.29
    Rect.: ECSL           4.85          .49         4.03    .77    0.77
  Displacement Velocity                                            
    Vel.: EODL            .73           .12         .47     .19    1.24
    Vel.: ECDL            .92           .08         .58     .13    4.12
    Vel.: EOSL            1.49          .11         1.50    .16    0.01
    Vel.: ECSL            2.50          .18         2.08    .26    1.74
  Cardiovascular                                                   
    Systolic BP           129.8         2.08        127.0   3.04   0.57
    Diastolic BP          80.5          1.26        73.7    1.80   9.35[^b^](#tfn5-ijtmb-5-3-28){ref-type="table-fn"}
    Heart Rate            67.0          1.29        67.5    1.90   0.07

*p* \< .01

Adj.M = covariate adjusted mean (baseline as covariate); SE = standard error; Area Rect = area rectangular; EODL = eyes-open double-leg; ECDL = eyes-closed double-leg; EOSL = eyes-open single-leg; ECSL = eyes-closed single-leg.

###### 

Fixed Effects Estimates of Postural Control Outcomes in Four Conditions: Rectangular Area of Displacement and Velocity

                          *Short-Term: Week 6: average rectangular area of displacement*          *Short-Term: Week 6: average displacement velocity*                                          
  ----------------------- ---------------------------------------------------------------- ------ ----------------------------------------------------- ----------------------- ------- ------ -----------------------------------------------------
  Rect. Area: EODL                                                                                                                                      Velocity: EODL                         
    Intercept             0.29                                                             0.44   0.65                                                    Intercept             0.21    0.17   1.25
    Time                  −0.04                                                            0.31   0.90                                                    Time                  0.09    0.09   0.96
    Treatment             0.63                                                             0.50   1.25                                                    Treatment             0.31    0.17   1.80+
    Baseline              0.49                                                             0.19   2.53[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}      Baseline              0.31    0.12   2.54[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −0.35                                                            0.37   −0.92                                                   Treatment ^\*^ Time   −0.20   0.11   −1.71+
  Rect. Area: ECDL                                                                                                                                      Velocity: ECDL                         
    Intercept             0.49                                                             0.19   2.53[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}      Intercept             0.34    0.12   2.89[^b^](#tfn8-ijtmb-5-3-28){ref-type="table-fn"}
    Time                  0.08                                                             0.11   0.76                                                    Time                  0.07    0.06   1.07
    Treatment             0.34                                                             0.20   1.73+                                                   Treatment             0.24    0.11   2.19[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
    Baseline              0.24                                                             0.08   2.78[^b^](#tfn8-ijtmb-5-3-28){ref-type="table-fn"}      Baseline              0.30    0.07   4.09[^c^](#tfn9-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −0.28                                                            0.13   −2.04[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}     Treatment ^\*^ Time   −0.17   0.08   −2.14[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
  Rect. Area: EOSL                                                                                                                                      Velocity: EOSL                         
    Intercept             0.76                                                             0.44   1.71+                                                   Intercept             0.71    0.22   3.22[^b^](#tfn8-ijtmb-5-3-28){ref-type="table-fn"}
    Time                  0.38                                                             0.24   1.60                                                    Time                  0.11    0.09   1.13
    Treatment             0.27                                                             0.48   0.56                                                    Treatment             0.14    0.19   0.73
    Baseline              0.25                                                             0.15   1.65                                                    Baseline              0.36    0.09   3.82[^b^](#tfn8-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −0.60                                                            0.28   −2.12[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}     Treatment ^\*^ Time   −0.27   0.11   −2.27[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
  Rect. Area: ECSL                                                                                                                                      Velocity: ECSL                         
    Intercept             2.39                                                             0.72   3.32[^b^](#tfn8-ijtmb-5-3-28){ref-type="table-fn"}      Intercept             0.84    0.34   2.43[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
    Time                  0.43                                                             0.46   0.92                                                    Time                  0.27    0.12   2.18[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment             1.33                                                             0.74   1.80+                                                   Treatment             0.56    0.33   1.71+
    Baseline              0.24                                                             0.09   2.58[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}      Baseline              0.46    0.08   5.89[^c^](#tfn9-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −0.33                                                            0.55   −0.60                                                   Treatment ^\*^ Time   −0.34   0.15   −2.30[^a^](#tfn7-ijtmb-5-3-28){ref-type="table-fn"}

*p* \< .05

*p* \< .01

*p* \< .001

B = unstandardized regression coefficient; SE = standard error; Rect. Area = rectangular area of displacement; EODL = eyes-open, double-leg stance; ECDL = eyes-closed, double-leg; EOSL = eyes-open, single-leg; ECSL = eyes-closed, single-leg.

###### 

Analyses of Covariance Predicting Outcomes 60 Minutes Post-TM (Adjusted for Baseline) at Week 6

                     *Treatment*   *Control*                 
  ------------------ ------------- ----------- ------ ------ -----------------------------------------------------
  Reflex Variables                                           
  PRD 2L             64.5          3.99        68.9   5.53   0.40
  RI 2L              57.1          3.75        52.1   5.06   0.62
  PRD 1L             66.5          2.74        63.4   3.80   0.44
  RI 1L              74.5          2.56        72.0   3.58   0.31
  H~max~/M~max~      0.19          0.02        0.30   0.03   11.6[^a^](#tfn11-ijtmb-5-3-28){ref-type="table-fn"}

*p* \< .05

Adj.M = covariate adjusted mean (baseline as covariate); SE = standard error; H~max~ = maximum Hoffman-reflex; M~max~ = maximum M-wave; PRD 2L = paired reflex depression 2 leg; PRD 1L = paired reflex depression 1 leg; RI 2L = recurrent inhibition 2 leg; RI 1L = recurrent inhibition 1 leg.

###### 

Results of Pearson's Correlation Comparisons of H-reflex and Postural Control Measures (Pearson's *r*) Week 6

  *Variable*        *Baseline*                                             *Post-Treatment*                                       
  ----------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  Area Rect. EODL                                                                                                                 
  Area Rect. ECDL                                                                                                                 
  Area Rect. EOSL   0.53[^a^](#tfn13-ijtmb-5-3-28){ref-type="table-fn"}                                                           −0.57[^b^](#tfn14-ijtmb-5-3-28){ref-type="table-fn"}
  Area Rect. ECSL                                                                                                                 
  V~Avg~ EODL                                                                                                                     
  V~Avg~ ECDL                                                                                                                     
  V~Avg~ EOSL                                                                                                                     −0.58[^b^](#tfn14-ijtmb-5-3-28){ref-type="table-fn"}
  V~Avg~ ECSL       −0.46[^a^](#tfn13-ijtmb-5-3-28){ref-type="table-fn"}   −0.44[^a^](#tfn13-ijtmb-5-3-28){ref-type="table-fn"}   

*p* \< .05

*p* \< .01

Area Rect = area rectangular; V~Avg~ = average velocity; PRD = paired reflex depression; RI = recurrent inhibition; EODL = eyes-open double-leg; ECDL = eyes-closed double-leg; EOSL = eyes-open single-leg; ECSL = eyes-closed single-leg.

###### 

Fixed Effects Estimates of Cardiovascular Outcomes

                          *Short-Term: Week 6*          
  ----------------------- ---------------------- ------ ------------------------------------------------------
  Systolic BP                                           
    Intercept             4 1.7                  12.7   3.27[^b^](#tfn17-ijtmb-5-3-28){ref-type="table-fn"}
    Time                  1.02                   1.60   0.63
    Treatment             3.51                   4.27   0.82
    Baseline              0.67                   0.09   7.17[^c^](#tfn18-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −4.24                  1.96   −2.17[^a^](#tfn16-ijtmb-5-3-28){ref-type="table-fn"}
  Diastolic BP                                          
    Intercept             10.6                   6.15   1.72
    Time                  0.45                   0.88   0.51
    Treatment             5.65                   2.18   2.58[^a^](#tfn16-ijtmb-5-3-28){ref-type="table-fn"}
    Baseline              0.84                   0.07   11.2[^c^](#tfn18-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   −2.31                  1.08   −2.13[^a^](#tfn16-ijtmb-5-3-28){ref-type="table-fn"}
  Heart Rate                                            
    Intercept             18.7                   5.70   3.27[^b^](#tfn17-ijtmb-5-3-28){ref-type="table-fn"}
    Time                  −0.55                  0.66   −0.82
    Treatment             0.10                   2.32   0.04
    Baseline              0.65                   0.08   8.19[^c^](#tfn18-ijtmb-5-3-28){ref-type="table-fn"}
    Treatment ^\*^ Time   0.89                   0.81   1.10

*p* \< .05

*p* \< .01

*p* \< .001

B = unstandardized regression coefficient; SE = standard error; BP = blood pressure.

###### 

Results of Analyses of Covariance Predicting Week 6 and Week 7 Outcomes (Adjusted for Week 1 Baseline)

                                 *Week 6 Outcomes*   *Week 7 Outcomes*                                                           
  ------------------------------ ------------------- ------------------- ------- ------ ---------- ------- ------ ------- ------ -----------------------------------------------------
  Motoneuron Pool Excitability                                                                                                   
    PRD2                         62.0                4.27                57.0    5.91   0.46       64.4    4.23   68.1    5.99   0.25
    RI2                          51.1                7.11                58.4    9.82   0.37       76.1    2.93   79.5    4.15   0.47
    PRD1                         61.3                4.38                60.9    6.08   0.01       72.0    3.63   65.7    5.14   1.00
    RI1                          71.9                7.54                70.5    10.4   0.01       82.2    3.26   72.6    4.62   2.82
    H~max~/M~max~                0.25                0.02                0.29    0.03   1.05       0.22    0.02   0.22    0.03   0.01
  Postural Control                                                                                                               
    Displacement Area                                                                                                            
    Rect.: EODL                  0.58                0.14                0.60    0.21   0.01       0.46    0.11   1.16    0.18   10.0[^b^](#tfn21-ijtmb-5-3-28){ref-type="table-fn"}
    Rect.: ECDL                  0.74                0.08                0.76    0.12   0.02       0.59    0.10   1.25    0.18   9.59[^b^](#tfn21-ijtmb-5-3-28){ref-type="table-fn"}
    Rect.: EOSL                  1.51                0.26                1.25    0.38   0.33       1.35    0.22   1.61    0.37   0.33
    Rect.: ECSL                  5.21                1.35                6.89    2.02   0.47       4.06    0.30   3.08    0.49   2.82
    Displacement Velocity                                                                                                        
    Vel. : EODL                  0.67                0.08                0.67    0.12   0.01       0.58    0.09   1.08    0.15   7.54[^a^](#tfn20-ijtmb-5-3-28){ref-type="table-fn"}
    Vel.: ECDL                   0.87                0.11                0.95    0.17   0.17       0.71    0.06   0.97    0.09   5.15[^a^](#tfn20-ijtmb-5-3-28){ref-type="table-fn"}
    Vel.: EOSL                   1.87                0.14                1.62    0.20   1.06       1.49    0.08   1.88    0.13   6.56[^a^](#tfn20-ijtmb-5-3-28){ref-type="table-fn"}
    Vel.: ECSL                   2.49                0.35                2.55    0.53   0.01       2.42    0.29   1.90    0.50   0.81
  Cardiovascular                                                                                                                 
    Systolic BP                  127.8               3.10                128.9   4.48   0.04       121.4   3.06   136.6   4.56   7.63[^b^](#tfn21-ijtmb-5-3-28){ref-type="table-fn"}
    Diastolic BP                 75.7                1.67                77.6    2.42   0.41       76.5    1.73   78.2    2.52   0.31
    Heart Rate                   76.1                2.02                67.7    2.92   5.60^\*^   71.0    2.13   69.0    3.18   0.26

*p* \< .05

*p* \< .01

Adj.M = covariate adjusted mean (week 1 baseline as covariate); SE = standard error; Rect. = rectangular area of displacement; PRD 2L = paired reflex depression 2 leg; PRD 1L = paired reflex depression 1 leg; RI 2L = recurrent inhibition 2 leg; RI 1L = recurrent inhibition 1 leg; EODL = eyes-open, double-legged stance; ECDL = eyes-closed, double-legged; EOSL = eyes-open, single-legged; ECSL = eyes-closed, single-legged; BP = blood pressure.

Immediate Treatment Effects: Week 6 Session
-------------------------------------------

The immediate pre- to post-TM effects at week six on balance and cardiovascular variables ([Table 3](#t3-ijtmb-5-3-28){ref-type="table"}) were assessed via ANCOVA in order to identify any increased instability resulting from TM. Although the TM group had higher adjusted means on most balance and cardiovascular variables (indicating some increase in instability), only the effect for diastolic blood pressure was statistically significant (F = 9.35, *p* \< .01).

Week Six Short-Term Post-Treatment Effects Across Time
------------------------------------------------------

### Postural Control Outcomes: Displacement Areas and Velocity

[Table 4](#t4-ijtmb-5-3-28){ref-type="table"} presents the short-term effects of TM (at week six) on the trajectories of the rectangular displacement area and velocity from immediate post-TM to 60-minutes post-TM. Rectangular area of displacement had a significant treatment X time interaction for the eyes-closed, double-leg stance ([Figure 2(a)](#f2-ijtmb-5-3-28){ref-type="fig"}). There was also a significant interaction for the eyes-open, single-leg condition. There were no treatment effects for area displacement in the eyes-closed, single-leg stance condition. Assessing average displacement velocity from immediately post-TM to 60-minutes post-TM, the treatment X time interactions for the eyes-closed, double-leg condition, the eyes-open, single-leg condition, and eyes-closed, single-leg conditions were significant ([Figure 2(b)](#f2-ijtmb-5-3-28){ref-type="fig"}). The significant downward trajectories in measures for these stances suggest that TM increased postural stability across these time points. The interaction for the eyes-open, double-leg stance condition only approached significance (t = −1.71, *p* \< .10).

### Nervous System Outcomes

Reflex variables were measured pretreatment and 60-minute post-TM. [Table 5](#t5-ijtmb-5-3-28){ref-type="table"} presents the ANCOVA results, assessing the treatment effects for the reflex variables. The TM group produced a significantly lower H~max~/M~max~ ratio than the control group (F = 11.6, *p* \< .05) at the 60-minute follow-up; there were no other significant effects. Pearson's correlations between H-reflex and balance measures revealed significant relationships in the single-leg stance ([Table 6](#t6-ijtmb-5-3-28){ref-type="table"}).

### Cardiovascular Outcomes

[Table 7](#t7-ijtmb-5-3-28){ref-type="table"} presents the short-term effects of TM (week six) on the cardiovascular variables from immediately post-TM to 60-minutes post-TM. The interaction of treatment condition with time was significant for both systolic and diastolic blood pressure. Blood pressure declined over time post-treatment for the TM group, but increased (or remained stable) for the control group ([Figure 3(c)](#f3-ijtmb-5-3-28){ref-type="fig"}). An order variable analysis (adding an order effect to the growth models, coded 0 for balance testing first, 1 for cardiovascular testing first) found that the timing change in assessing cardiovascular measures had an effect only for systolic blood pressure \[B = 0.65, SE = 0.08, t(29.5) = −2.14, *p* \< .05\], indicating lower BP for participants assessed prior to the balance assessments), but the treatment effect was unchanged for this outcome and in all cardiovascular measures.

![Short term post-treatment postural control displacement (a),velocity (b), and systolic blood pressure (c) trajectories at week 6 (measure across time: 0, 20 and 60 min time points).\
Post = measures taken immediately after the TM session; 20 = 20 minutes after TM session; 60 = 60 minutes after TM; EODL = eyes-open double-leg; ECDL = eyes-closed double-leg; solid line = treatment group; dashed line = control group.](ijtmb-5-3-28f3){#f3-ijtmb-5-3-28}

Long-Term Treatment Effects: Week Six and Seven
-----------------------------------------------

### Postural Control Outcomes: Displacement Area and Velocity

An ANCOVA compared the two groups on week six presession baseline and week seven displacement area and velocity measures, adjusted for week 1 baselines ([Table 8](#t8-ijtmb-5-3-28){ref-type="table"}). ANCOVA also compared the two groups on week seven stability measures, adjusted for week 1 baselines. There were no significant group differences at week six for any displacement outcome. By week seven, the treatment group had significantly lower displacement area and velocity in multiple conditions. There were no significant group differences for any balance measure at week seven in the eyes-closed, single-leg condition.

### Nervous System Outcomes

An ANCOVA compared the two groups on week six and week seven reflex measures ([Table 8](#t8-ijtmb-5-3-28){ref-type="table"}). There were no significant group differences on any reflex variable. Thus, although the H~max~/M~max~ ratio showed immediate treatment effects, there was no significant difference in baseline reflex measures over the long term.

### Cardiovascular Outcomes

An ANCOVA compared the two groups on week six and week seven cardiovascular measures ([Table 8](#t8-ijtmb-5-3-28){ref-type="table"}). There was no significant group difference in systolic blood pressure at week six, but by week seven the TM group was significantly lower. There was no significant group difference for diastolic blood pressure at week six or week seven. The TM group was significantly in higher heart rate at week six, but there was no significant difference by week seven. Adjustment for our protocol change (order effect) had no effect on any outcome.

DISCUSSION
==========

Immediate Treatment Effects
---------------------------

This study examined the effects of six weekly 60-minute, full-body TM treatments compared to a resting control group on balance, nervous system, and cardiovascular measures in healthy, older adults. The immediate treatment effects at week six were assessed pre- and post-treatment in order to examine potential increases in instability immediately after a TM treatment ([Table 3](#t3-ijtmb-5-3-28){ref-type="table"}). As with study one which assessed these changes at week one, no increase in instability occurred immediately after TM. Increased instability would have suggested that additional safety measures should be utilized, especially with older adults who tend to have decreased postural stability^([@b17-ijtmb-5-3-28])^. There was a tendency for increased means in the balance measures, suggesting some participants may be more unstable after the treatment. These results support what is seen clinically, and suggest current safety measures are appropriate and should be continued. Adjusted means for diastolic blood pressure were higher immediately after the TM in the treatment group compared to the control group, with no differences in other cardiovascular measures. No differences between groups were found in these measures in study one. Most studies indicate a decrease in cardiovascular measures after TM^([@b28-ijtmb-5-3-28],[@b39-ijtmb-5-3-28]--[@b40-ijtmb-5-3-28])^. However, the timing of the readings in relation to the treatment is often not noted and may be a factor. [Figure 3(c)](#f3-ijtmb-5-3-28){ref-type="fig"} indicates the change in systolic blood pressure over time (diastolic was similar). Thus, the timing of the measurements could strongly influence the results.

Week Six Short-Term Post-Treatment Effects Across Time
------------------------------------------------------

Treatment effects on balance and cardiovascular measures were assessed immediately post-TM to 60 minutes post-TM to determine any differences that occur the 60 minutes after a treatment. Differences in the measures across time would also suggest that researchers should note specifically when measures are taken in order to assist in comparisons between studies and to further our understanding of treatment effects.

Short-term treatment effects on rectangular area and displacement velocity during week six revealed significant downward trajectories relative to controls from immediate post-treatment to 60 minutes post-treatment in several of the stances ([Figures 3(a) and (b)](#f3-ijtmb-5-3-28){ref-type="fig"}, [Table 4](#t4-ijtmb-5-3-28){ref-type="table"}). The eyes-open, single-leg and eyes-closed, double-leg stances seemed to provide an appropriate challenge without being too difficult for the participants to complete. The eyes-open, double-leg stance may have not have provided enough challenge; while the eyes-closed, single-leg stance proved to be too difficult. Together, these findings suggest an increase in postural stability through the 60-minute test period after TM when compared to the control group.

Nervous system measures ([Table 5](#t5-ijtmb-5-3-28){ref-type="table"}) were taken pre-TM and 60 minutes post-TM only, and at the same time points for the control group. These measures revealed a significantly lower adjusted mean in H~max~/M~max~ ratio 60 minutes in the treatment group compared to the control group; no differences in the other nervous system measures were revealed. This decrease was of the same magnitude as found in part one of this study, indicating that the additional 6 weeks of treatment did not influence the pre- to post-TM effects of the single session. H~max~ indicates how much of the motoneuron pool is recruited during testing, compared to M~max~ which represents full recruitment of the motoneuron pool. Thus, the H~max~/M~max~ ratio indicates the proportion of the motoneuron pool that is recruited during testing^([@b37-ijtmb-5-3-28])^. The H~max~/M~max~ ratio decrease suggests the treatment had a physiological effect on the neuromuscular system, with fewer motoneurons recruited during a contraction. This may be influenced by training, injury, treatments or other factors. A lower adjusted mean H~max~/M~max~ ratio in the treatment group could indicate a decrease in muscle fatigue compared to the control group; however, more work would need to be completed to quantify muscle fatigue after TM.

Cardiovascular measures of systolic and diastolic blood pressure also followed a significant decreasing trajectory from immediate post-treatment to 60 minutes post-treatment in the treatment group compared to the control group ([Figure 3(c)](#f3-ijtmb-5-3-28){ref-type="fig"}, [Table 7](#t7-ijtmb-5-3-28){ref-type="table"}). This decrease was expected and has been previously reported^([@b28-ijtmb-5-3-28],[@b39-ijtmb-5-3-28])^. Interestingly, no changes in heart rate were found. While the effect of TM on cardiovascular measures and blood flow has been reported, some results are conflicting^([@b28-ijtmb-5-3-28],[@b30-ijtmb-5-3-28],[@b40-ijtmb-5-3-28])^. Additional research on these effects and mechanisms behind these changes is needed and may reveal a potential for TM as a nonpharmaceutical treatment for elevated blood pressure. It must be kept in mind that individuals may respond differently to TM, as they do to medications. An individual uncomfortable with touch may not respond with a decreased blood pressure. Blood pressure medications all have possible side effects and interactions with other medications, vitamins, and food including increased urination, sexual effects, weakness, leg cramps, fatigue, asthma, depression, sleep issues, skin rash, loss of taste, cough, and other concerns^([@b41-ijtmb-5-3-28])^. Clearly, any intervention must consider the individual as a whole and develop the best possible combination of treatments for the health and wellness of the patient.

Further assessment of most measures revealed an increase in the control trajectories from immediate post- to 60 minutes post-treatment. This is confirmed by looking at the raw means in Table 2([b](#t2b-ijtmb-5-3-28){ref-type="table"}--[c](#t2c-ijtmb-5-3-28){ref-type="table"}). This may be a fatigue factor caused by the long study period required for pretesting, resting for an hour, and then repeating the testing three times post-treatment through the 60-minute time period. Treatment group participants completed the same protocols; however, they received the TM which may have influenced any fatigue factor.

Long-Term Treatment Effects: Week Six and Seven
-----------------------------------------------

The long-term effects of the treatment were compared to the control condition on balance, nervous system, and cardiovascular measures at the pretreatment time point for week six and at week seven ([Table 8](#t8-ijtmb-5-3-28){ref-type="table"}). Week seven was a follow-up, non-treatment week with all participants coming in for testing only.

Assessment of balance at week six indicated no significant differences between the treatment and control groups. However, by week seven there were significantly lower values in the treatment group for rectangular displacement area and velocity in several stance conditions, suggesting an improved ability to maintain balance at week 7. This result, and the timing of the benefits of TM, is an interesting finding worthy of further investigation.

Although short-term changes after treatment in motoneuron pool excitability were evident, analysis of the reflex data ([Table 8](#t8-ijtmb-5-3-28){ref-type="table"}) revealed no significant long-term changes at week six or week seven. Single-leg RI, which would be more likely to demonstrate long-term influences, did approach significance (F = 2.82, *p* = .10) at week seven. The lack of long-term effects on reflex variables is consistent with what we know about how reflexes function. Spinal reflexes provide the body with an immediate response to environmental change (internal and external). This study design looked for simple changes in reflex response after long-term treatment. It may be that to determine the influence of TM on spinal reflexes, a better design would be to assess reflex response to challenges before and after treatment. This will be a focus of future work.

Long-term cardiovascular measures again revealed no significant differences at week six; however, by week seven there were significantly lower systolic blood pressures in the treatment group compared to baseline controls. No differences were found in diastolic blood pressure at either week compared to baseline controls. Interestingly, heat rate was higher week six for the treatment group, but there were no differences found at week seven. Clearly, more work needs to be done to understand the influence of weekly TM on cardiovascular measures, and to determine if the timing of the tests influences the results.

The immediate effects at week six were similar to a previous study in our lab (in press) analyzing the effects of a single session of TM. It may be that the pre- to post-treatment effects of TM are immediate and consistent across time. It may also be that long-term benefits are perhaps just beginning to occur after six weekly treatments. The changes after seven weeks were fairly robust, making longer studies to investigate these effects over time warranted. It is also interesting to note that these changes were found after one week of nontreatment. Research investigating how long any treatment effects are maintained should be undertaken. A recent study assessed eight weeks of TM for knee osteoarthritis, with a follow-up study to establish an optimal TM dose^([@b42-ijtmb-5-3-28])^. Few other studies assessing long-term effects of massage have been conducted^([@b43-ijtmb-5-3-28]--[@b44-ijtmb-5-3-28])^. Clearly more work needs to be completed in this area. Finally, it should be noted that the effects of most medications are short-term, and end once the patients stops taking the medication. Any extended effects of TM would suggest that this treatment should be considered along with, or in place of, standard medical interventions.

Limitations of this study include the use of healthy, older participants; results may differ with individuals experiencing conditions common with aging such as osteoarthritis, high blood pressure or diabetes. Our participants were an average of 62.9 years of age, making them young on the spectrum of older adults. Also, our participants self-selected to join our study. While posters and word of mouth were used to access all ranges of the older population, it is anticipated that those that were more healthy and with previous positive touch experiences were more likely to volunteer. This was an introductory study and results may vary with a less healthy or older population; a larger study should be conducted to include a wider range or older adults. Additionally, the control group simply rested between testing session rather than receiving a treatment, and completed daily activities as usual. Use of an alternative treatment would provide interesting comparisons. If research can show that TM produces improvements in balance, nervous system, and cardiovascular measures which increase over time and are maintained after therapy ceases, this would be a substantial finding strongly promoting this treatment as a nonpharmaceutical intervention for falls in older adults.

CONCLUSION
==========

A single session of TM produced an immediate postsession elevation in diastolic blood pressure and no increase in postural instability compared to the controls. From immediate post-treatment to 60-minute follow-up, displacement area/velocity and blood pressure decreased in the TM group at week six. Long-term benefits of TM at week seven were detected in displacement area/velocity and systolic blood pressure. Results suggest six weeks of TM resulted in immediate and long-term improvements in stability and blood pressure in older, healthy adults.
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